SLS vs. ELDN, CLRB, NEOS, CORV, NKTX, AVIR, SKYE, SBTX, ANRO, and URGN
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Eledon Pharmaceuticals (ELDN), Cellectar Biosciences (CLRB), Neos Therapeutics (NEOS), Correvio Pharma (CORV), Nkarta (NKTX), Atea Pharmaceuticals (AVIR), Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Alto Neuroscience (ANRO), and UroGen Pharma (URGN). These companies are all part of the "medical" sector.
Eledon Pharmaceuticals (NASDAQ:ELDN) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, community ranking, analyst recommendations, valuation, institutional ownership and dividends.
SELLAS Life Sciences Group's return on equity of -45.60% beat Eledon Pharmaceuticals' return on equity.
Eledon Pharmaceuticals received 16 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 72.22% of users gave Eledon Pharmaceuticals an outperform vote while only 58.82% of users gave SELLAS Life Sciences Group an outperform vote.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
Eledon Pharmaceuticals currently has a consensus price target of $11.67, indicating a potential upside of 319.66%. SELLAS Life Sciences Group has a consensus price target of $3.00, indicating a potential upside of 106.90%. Given SELLAS Life Sciences Group's higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than SELLAS Life Sciences Group.
SELLAS Life Sciences Group has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eledon Pharmaceuticals had 8 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 9 mentions for Eledon Pharmaceuticals and 1 mentions for SELLAS Life Sciences Group. Eledon Pharmaceuticals' average media sentiment score of 1.73 beat SELLAS Life Sciences Group's score of 0.94 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media.
Summary
Eledon Pharmaceuticals beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.
Get SELLAS Life Sciences Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
